公开(公告)号：US20190336514A1

公开(公告)日：2019-11-07

申请号：US16402589

申请日：2019-05-03

Applicant: Amgen Inc.

Inventor： Ryan Paul WURZ ,  Victor J. CEE ,  Albert AMEGADZIE ,  Ning CHEN ,  Brian Alan LANMAN ,  Michael D. BARTBERGER

IPC: A61K31/675 ,  A61P35/00 ,  A61K31/553 ,  A61K31/167 ,  C07K16/30

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US20240082251A1

公开(公告)日：2024-03-14

申请号：US18503009

申请日：2023-11-06

Applicant: AMGEN INC.

Inventor： Haby HENARY ,  James Russell LIPFORD ,  Victor J. CEE

IPC: A61K31/519 ,  A61K31/53 ,  A61K31/5375 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K31/53 ,  A61K31/5375 ,  A61P35/00

Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

公开(公告)号：US20230028414A1

公开(公告)日：2023-01-26

申请号：US17785852

申请日：2020-12-15

Applicant: AMGEN INC.

Inventor： Haby HENARY ,  James Russell LIPFORD ,  Victor J. CEE

IPC: A61K31/519 ,  A61K31/5375 ,  A61K31/53 ,  A61P35/00

Abstract: Provided herein are methods of administering a KRAS G12C inhibitor to a cancer subject.

公开(公告)号：US20220213101A1

公开(公告)日：2022-07-07

申请号：US17692026

申请日：2022-03-10

Applicant: Amgen Inc.

Inventor： Brian Alan LANMAN ,  Shon BOOKER ,  Clifford GOODMAN ,  Anthony B. REED ,  Jonathan D. LOW ,  Hui-Ling WANG ,  Ning CHEN ,  Ana Elena MINATTI ,  Ryan WURZ ,  Victor J. CEE

IPC: C07D471/04 ,  A61P35/00 ,  A61K31/519

Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US20200055845A1

公开(公告)日：2020-02-20

申请号：US16661907

申请日：2019-10-23

Applicant: Amgen Inc.

Inventor： Brian Alan LANMAN ,  Jian CHEN ,  Anthony B. REED ,  Victor J. CEE ,  Longbin LIU ,  David John KOPECKY ,  Patricia LOPEZ ,  Ryan Paul WURZ ,  Thomas T. NGUYEN ,  Shon BOOKER ,  Nobuko NISHIMURA ,  Youngsook SHIN ,  Nuria A. TAMAYO ,  John Gordon ALLEN ,  Jennifer Rebecca ALLEN

IPC: C07D417/04 ,  C07D475/00 ,  C07D275/04 ,  A61K31/7068 ,  A61P35/00 ,  A61K31/5025 ,  A61K31/502 ,  A61K31/519 ,  A61K31/517 ,  A61K31/454 ,  A61K31/55 ,  A61K31/416 ,  A61K31/496 ,  C07D403/04 ,  C07D237/34 ,  C07D401/14 ,  C07D239/80 ,  C07D401/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D513/04 ,  C07D417/12 ,  C07D487/08 ,  A61K38/07

Abstract: Provided herein are methods of using KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US20200030324A1

公开(公告)日：2020-01-30

申请号：US16428163

申请日：2019-05-31

Applicant: Amgen Inc.

Inventor： Shon BOOKER ,  John Gordon ALLEN ,  Brian Alan LANMAN ,  Ryan Paul WURZ ,  Ning CHEN ,  Victor J. CEE ,  Patricia LOPEZ ,  Aaron C. SIEGMUND ,  Michael D. BARTBERGER

IPC: A61K31/497 ,  C07K16/28

Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

公开(公告)号：US20140336182A1

公开(公告)日：2014-11-13

申请号：US13893182

申请日：2013-05-13

Applicant: Amgen Inc.

Inventor： Victor J. CEE ,  Holly L. DEAK ,  Bingfan DU ,  Stephanie D. GEUNS-MEYER ,  Zihao HUA ,  Matthew W. MARTIN ,  Isaac MARX ,  Hanh Nho NGUYEN ,  Philip R. OLIVIERI ,  Kathleen PANTER FABER ,  Karina ROMERO ,  Laurie SCHENKEL ,  Ryan WHITE

IPC: C07D495/04 ,  C07D491/048 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D495/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D491/048

Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Abstract translation: 本发明涉及具有通式I的化合物，其中A1-8，D'，L1，L2，R1，R6-8和n定义在本文中，以及合成中间体，其能够调节各种蛋白激酶受体酶和 从而影响与这种激酶的活性相关的各种疾病状态和状况。 例如，化合物能够调节Aurora激酶，从而影响细胞周期和细胞增殖的过程，以治疗癌症和与癌症有关的疾病。 本发明还包括药物组合物，包括该化合物，以及治疗与Aurora激酶活性有关的疾病状态的方法。